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Placebos have attracted widespread interest amongst anthropologists who have sought to 
explain the placebo dimension of medicines or healing rituals prescribed by health profes-
sionals or traditional healers by emphasizing aspects relating to symbolic healing. Very 
little investigation has been done however into the perceptions individuals hold of placebos, 
and their reasons for resorting to placebos and/or the placebo effect within the framework 
of family medication, on one hand, and the perception pharmacists have on this issue and 
the uses they make of it in their responses to the demands of users, on the other. This article 
addresses their uses of placebos and the placebo effect within the context of medicinal risk 
management in France; it also examines the perception actors have of placebos (whether 
‘pure’ or ‘impure’) in the light of their ethical positions.  
Introduction
Scholars from numerous disciplines have taken an interest in placebos and have 
proposed diverse approaches: historical, epistemological, physiological, neurolo-
gical or psychological (Benedetti et al., 2005; Benedetti et al., 2011 ; Jensen et al., 
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2014; Mayberg et al., 2002). The notion of the placebo is used in two very different 
contexts: in research practice and in routine care. When the use of placebos is exa-
mined, it is generally done either to show the position they occupy in trials of new 
medicines and to determine their effect – what Boussageon (2008) calls the ‘dark 
side’ of the controlled clinical trial – or to show that they are used by practitioners 
within the framework of their clinical activity. 
Anthropology in turn, has been particularly interested in the ‘placebo effect’1. 
The discipline has demonstrated the placebo dimension of treatments prescribed 
by health professionals or traditional health practitioners beyond the constituent 
elements of these treatments. In emphasizing aspects relative to symbolic healing, 
anthropological studies have in particular underlined the placebo effect of thera-
peutic rituals (Peters, 2001; Ostenfeld, 2012), shown the existence of cultural va-
riations in the placebo effect (Moerman, 2000; Helman, 2001), demonstrated that 
the interpretation of the placebo effect depends on the context (Thompson, Riten-
baugh & Nichter, 2009), and have related their thinking on the subject to the que-
stion of belief (Cathebras, 2008) – to such a degree in fact that in biomedicine the 
term the ‘placebo effect’ is often used to encompass everything related to symbolic 
healing, as Whyte, Van der Geest & Hardon (2002) have noted.    
Although many studies have focused on the use of placebos in clinical practice, 
very little investigation has been done on the perceptions individuals hold of pla-
cebos and their reasons for resorting to placebos and/or the placebo effect within 
the framework of family medication, on one hand, and the perceptions and uses 
of pharmacists in response to the demands of clients, on the other. 
 This is what I propose to examine in this article in the context of France. Indeed, 
nowadays placebos not only play an important role in medical practice, they also 
constitute part of the work in officinal practice - although there is no consensus as 
to the ethical or unethical nature of selling a placebo to a patient seeking medical 
treatment. The article will describe this informal practice, and people’s thoughts 
about the values and the risks of administering placebos, whether this is done by 
consulting a pharmacist or within the framework of family medication. My aim in 
analysing these representations and practices is to contribute to anthropological 
reflection on the social uses in this field.   
My reflection will cover the uses placebos are put to, which we will see are 
generally positioned within the context of the management of the risk associated 
with medicines, and the perception actors have of placebos in the light of their 
ethical positions. Therefore, I am not looking here to define what makes the place-
bo effective or what creates the placebo effect2, but the perceptions and social uses 
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of placebos by the very people who know the treatment is a placebo or a medicine 
from which they expect a placebo effect. Evidently, people cannot discuss their 
use of placebos on themselves since, to have an effect, the placebo has to be viewed 
as real medicine. So, they are not talking about their own use of placebos (except 
in retrospect), but of situations where they know they are using a placebo while 
the intended recipient does not. In other words, it is a case of defining what deter-
mines recourse to a placebo as an object likely to produce an effect even though it 
is perceived as a substance devoid of intrinsic efficacy – a recourse that takes place 
either in secret at home, or in collaboration with a pharmacist.  
This reflection is based on materials gathered during three studies carried out 
in France. The first examined patient behaviour regarding medicines and pre-
scriptions. It was carried out in the south of France and involved 186 patients 
living in both urban and rural areas, from different religious and cultural back-
grounds, and belonging to very diverse socio-professional categories (Fainzang, 
2001, 2005). The second study focused on self-medication. It explored the different 
problems for which the respondents had sought treatment for themselves or for 
their family, the conditions under which they chose either to consult a doctor or to 
treat themselves, the resources they used to identify the problem and to select the 
appropriate treatment, the strategies they adopted to ensure a satisfactory risk-
benefit ratio, etc. It was carried out in Paris and involved forty people, belonging 
to the different social milieus that can be included in the term the “middle classes” 
which nowadays covers the intermediate classes and part of what used to be the 
working and upper classes (Fainzang, 2012, 2013). The third one, still in progress, 
addresses lay management of medicinal risks. It is also being carried out in the 
Paris region, with people belonging to the “middle classes” (Fainzang, 2014).
All three research projects involved people of both sexes and from various 
socio-professional backgrounds. The people studied were met on several occasi-
ons, in order to understand (through their gestures, words and actions) their sy-
stems of thought. Some were met through the “snowball” method, others through 
the intermediary of health professionals. The research was mostly carried out at 
people’s homes, and thus consisted for a large part of interviews - even if, in some 
cases, the interviews were combined with in situ observation concerning the choi-
ces people made when experiencing or dealing with a symptom. Moreover, I col-
lected information from the informants on the conditions in which the drugs de-
tained in their household medicine cabinets were acquired and used. The material 
collected also resulted from observations of consultations, and from interviews 
with pharmacists throughout the research processes. 
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Thus, the material on which this article is based was gathered within a research 
framework where the main subject was not the placebo but medicinal use; howe-
ver, the issue of placebos was addressed during these interviews. This paper focu-
ses on patients’ and pharmacists’ discourses and practices with regard to placebos 
in the context of their behaviour regarding their perception of pharmaceutical 
risks. With the added perspective of data provided by literature on the prescrip-
tion of placebos by doctors, I will present here information on the use of placebos 
by people themselves, and the role played by pharmacists in response to demand 
from clients, along with their practices and their ethical postures. Contrasting 
attitudes exist among both patients and pharmacists: fears, hesitancies and ca-
tegorical refusals, but also hopes, passions and even ambivalent feelings. These 
attitudes cross over and converge with both the therapeutic and ethical options. 
We will see in particular that while individual practices depend on heterogeneous 
philosophical and pragmatic positions, acceptance (or refusal) of the use of place-
bos is often the result of a compromise between the desire to avoid taking a risk in 
the therapeutic register and a desire to avoid doing so in the ethical one. 
Placebos in medical prescriptions
In clinical practice today, it is established that the placebo effect is much larger 
than is traditionally thought, since it also exists for verum, and that the placebo ef-
fect should not be perceived as a pollutant (Cathebras, 2006) but as a fundamental 
ingredient in therapeutic efficacy. This phenomenon has led to a distinction in the 
medical milieu between ‘pure’ and ‘impure’ placebos. The ‘pure’ placebo, which is 
totally devoid of pharmacodynamic action, is created by inert substances with no 
physiological nor pharmacological effect. The ‘impure’ placebo is a medicine with 
no proven pharmacological activity in the situation in which it is employed, or an 
efficacious medicine used for other indications, in other words, it is prescribed in a 
situation where this efficacy has not been demonstrated, and where the relations-
hip the patient has formed between the molecule and his/her affliction is due to a 
placebo mechanism (Spiro 1986).  
The literature on the subject shows such prescriptions. Using a large study car-
ried out in the UK, Howick et al. (2013) show that many doctors reported having 
prescribed placebos in their careers, by concealing from the patients that the pre-
scribed substance had no active ingredients3. Equally, a study on the prescription 
of placebos in the United States (Tilburt J. et al, 2008) showed that almost one in 
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two doctors (46%) regularly prescribe placebos several times a month. 2% of the 
placebos prescribed are sugar pills, 3% saline solutions, and only 5% of doctors 
discuss the issue of placebos with their patients.   
In France too, doctors sometimes resort to prescribing placebos to their patients 
although, here too, they are often ‘impure’ placebos. The Vidal Drug Compendi-
um (a French medical work that brings together summaries of the characteristics 
of products from pharmaceutical laboratories) is known to contain nearly 50% 
of so-called ‘impure’ placebos (Spiro 1986). The frequency of such prescription is 
difficult to establish. According to P. Maire (2008), while impure placebos are still 
prescribed today in non-hospital medicine, pure placebos are rarely prescribed 
as such, contrarily to circumstances twenty years ago in hospitals, a difference 
he attributes to the increased ethical awareness recently expressed in charters of 
patients’ rights. It is difficult to ascertain real figures for placebo prescriptions 
since doctors often deny such use, or only discuss it amongst colleagues. Hofling 
(1955) had already noted that the majority of practitioners were convinced they 
resorted to the prescription and use of placebos less often than their colleagues. 
And numerous doctors today still mention the topic to say that other doctors use 
them, but they do not. 
Doctors generally justify such prescriptions when presented with symptoms 
they judge not particularly serious or those they diagnose as functional or psy-
chological, or when they have no other therapeutic solution or they believe that a 
genuine analgesic is not appropriate for the patient since it could provoke adverse 
side-effects. But a medicine can be genuine (with marketing authorisation and an 
indication conforming to the context in which it is prescribed) but nevertheless 
considered as a placebo by the doctor. Thus, Dr C, a rheumatologist, regularly 
prescribes anti-arthritics even though he says that no study has yet proven their 
efficacy. He considers them to be placebos and prescribes them so that they act 
as placebos on the patients. As we can see, the distinction between ‘pure’ and 
‘impure’ is not sufficient to account for all the uses of placebos in clinical practice 
since the situation proves to be much more complex.  
The anthropological literature nevertheless demonstrates the persistence of 
such uses. Observations led by Anne Vega (2011) show that some doctors, amongst 
those she calls the ‘little prescribers’, replace sleeping pills with placebos and pro-
gressively un-prescribe the psychoactive drugs that their new patients are taking, 
with the aim of reducing their medicinal consumption. Moreover, some doctors 
publicly declare their use of this type of prescription when they judge a medici-
nal prescription to be useless. The president of the French National Syndicate of 
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Young GPs thus told the Express newspaper: ‘It can happen that we prescribe pla-
cebos […]. Some patients find leaving the doctor’s cabinet without a prescription 
difficult to understand.’ (The Express, 2012).  
Prescriptions of placebos are mainly given for pain and insomnia, even if, ac-
cording to Beecher (1955), all pathologies are susceptible to the placebo effect. Ac-
tually, the extent of the placebo effect is a subject of controversy. In contrast to 
Beecher, Jean-Jacques Aulas (2008) believes that the placebo effect does not apply 
to all pathologies and that it only works on pathologies with a strongly subjective 
component, in particular on pain, anxiety, sleeping problems, moderate depres-
sion and psychofunctional complaints, which make up a large part of the reasons 
for consulting a GP; whereas, for his part, Zigmond (1984) notes that it is well 
established that placebos can have a positive therapeutic effect in a very wide 
range of disease processes in any bodily system.
Placebos in family medication
The placebo effect is often attributed to the ‘doctor effect’ (Moreau, 2008 ; Brody, 
1997), or to what Pignarre (2008) refers to as the ‘white coat effect’ (p. 91), parti-
cularly since Michael Balint (1957) famously wrote that the most frequently used 
drug in general medicine is the doctor him/herself (p. 9). In this regard the quality 
of the therapeutic relationship between clinician and patient has also been discus-
sed (Thompson, Ritenbaugh & Nichter, 2009), as well as ‘trust’ in the prescribing 
doctor, which everyone agrees is a prerequisite for the placebo effect to work. In 
the literature, the use of placebos for therapeutic ends is in fact always discussed 
within the framework of clinical practice. Thus, when Thompson, Ritenbaugh & 
Nichter (2009) describe the domains in which the placebo is used, they only men-
tion clinical research and clinical practice. Equally, Thalabard (2008) believes that 
the placebo can only be used when the decision comes from the doctor.  
However, there exists a social configuration that is never explored, where indi-
viduals choose to resort to a placebo for a family member within the framework 
of family medication. The placebo effect itself, which is generally portrayed as the 
result of an interaction between doctor and patient, can also occur when a product 
is administered outside of medical prescriptions. It is these domestic uses that are 
of interest here, and I will attempt to understand their mechanisms of use and the 
logics that underpin them.  
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Indeed, some lay uses of the placebo can be observed, meaning the initiative of 
people who give or advise placebos, or medicines they hope will have a placebo 
effect, to members of their family. It can be a case of a person (generally a woman) 
doing so for her spouse or elderly parent, or of a parent (most often the mother) for 
her child. These uses are, for a large part, in line with the logics and the concerns 
behind doctors’ prescriptions. The person is trying to avoid giving a real pharma-
ceutical to a family member when he/she thinks that this is not necessary or that 
the symptom is not serious, when the aim is to avoid a pointless consumption of 
medicines. Or the person gives a different medicine from that with the correspon-
ding indications for the affliction in question when that allows the risks involved 
in administering the correctly indicated drug to be avoided. In all these cases, fa-
mily use of a placebo aims to mitigate the risks associated with consuming certain 
medicines.
Thus, we can see that placebos are employed within the family, as the follo-
wing examples show. Mrs G, whose 10-year-old daughter had a cough, had asked 
her doctor to prescribe a cough medicine, but he had advised her not to use such 
medicines and suggested she confine herself to using the pharyngitis treatment 
he had given her previously. Instead she made a pure placebo using grenadine 
cordial with added sugar and a small amount of flour to thicken it. Mrs A, for her 
part, gives her son paracetamol when he complains of problems getting to sleep. 
She refuses to give him a tranquilizer since she is against the use of psychoactive 
drugs, ‘especially for children’, she explained. Even though she considers parace-
tamol to be a real medicine, she does not believe it has any tranquilizing proper-
ties, but she uses it in the hope it will have a placebo effect on her son; ‘at least, 
there is no risk’, she explained4. The aim is to avoid using a medicine considered 
risky and to substitute it for another thought to be devoid of harmful effects while 
making the person being treated believe that it has the same properties. Here, she 
uses an ‘impure placebo’ as it carries an active principle but for a different indica-
tion. Yet, the notion of an ‘impure placebo’ is relatively unknown to the public. It 
is an etic definition, recognized by the specialists working on this issue within the 
framework of clinical practice. At the emic level, people speak of ‘placebos’ to refer 
to the use of substances from which they expect a placebo effect, whether these are 
authentic medicines or not.  
Use of a pharmaceutical can be accidental and its effect can sometimes be disco-
vered by chance during or after a treatment. Mrs B. explained she had ‘miscast’ a 
medicine (to mean there was no link with the use for which it is indicated), having 
confused two medicines with similar names. This type of mistake can happen 
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when there is a similarity between the boxes, the pills themselves or the commer-
cial names of different proprietary drugs. One evening, she was suffering from 
insomnia which she wanted to tackle by taking a soporific drug, but instead she 
took a medicine indicated for digestive problems, which turned out to be effective, 
she thought, since she then managed to get to sleep. She only noticed her mistake 
the next day. Convinced that this medicine contained a molecule that helped her 
to relax, she continued taking it for this purpose during the periods she experien-
ced difficulties in getting to sleep.    
Discovering a mistake, even when an improvement has occurred, does not 
however always lead to reuse of the medicine in question. One evening, Mr H, 
who suffered from muscular pain in his arm, coated the muscle in an antihistami-
nic cream (that he had once bought to treat mosquito bites), thinking he was using 
an anti-inflammatory cream. The following day, when his muscle appeared to be 
hurting less, he noticed his mistake. He concluded that the cream he had used the 
day before had had a placebo effect, since when he thought it was appropriate for 
his pain, it had relieved it. Nevertheless, he regrets that it can no longer work on 
him since he is now aware that using it is inappropriate and the trickery he had 
involuntarily exposed himself to cannot be repeated.  
And finally, a placebo can be used in order to ensure that the symptom the sub-
ject is complaining of is indeed serious. This is particularly the case for children 
and elderly people. When her children complain of pain, Mrs L experiments with 
the use of what she considers to be placebos and then if the pains go away or di-
minish, she judges them to be not serious or even devoid of pathological character. 
This can be called the diagnostic use of the placebo.  
However, research into the domestic uses of medicines reveals that more com-
plex situations exist, where the substance used takes on an ambivalent or different 
status depending on the person. This is the case for homeopathy, which some 
people buy without believing in the existence of any active ingredient, but from 
which they expect a placebo effect on their child. Some people choose to resort to 
a product to which they assign exclusively placebo properties, in the manner of 
the rheumatologist with the anti-arthritics mentioned above, while others credit 
the product with an intrinsic efficacy. One man who was worried about his mo-
ther regularly taking Seresta (an anxiolytic of the benzodiazepine family) to get 
to sleep, bought her Cocculine (a homeopathic medicine sold for travel sickness) – 
even though he was convinced that homeopathy had no innate efficacy – because 
he thought these homeopathic granules looked like the Seresta pills. This phen-
omenon can also be observed amongst pharmacists, whose practices it is worth 
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examining since recourse to placebos in family medicine is sometimes carried out 
with the complicity of health professionals, whether they actually make a ‘pure’ 
placebo or provide advice on an ‘impure’ one.   
Placebos in officinal practice
The interviews carried out with pharmacists concerning their experience on the 
subject reveal some contrasting perceptions of what a placebo is. Some occasio-
nally make and dispense true placebos:  
It can happen that I give a placebo. Around ten or fifteen years ago, I had a patient 
who was taking Tranxene 10; it was a young 19-year-old man. His father was very 
worried about it and he wanted his son to get out of the habit. ‘It’s in his head,’ he 
told me. He asked me to take the tablets and put something else inside. I thought of 
putting lactose in, but I asked his GP anyway. ‘Why not?’, he said to me, ‘we can try 
it’. It’s true he was taking it out of habit. We gave him lactose for several months and 
he ended up stopping, I suppose, because I still see him, but without a Tranxene 
prescription. (PZ, ph5)
There are clients who ask me for something harmless for family members. Espe-
cially for sleeping problems, to avoid taking anxiolytics. One day, I made one up 
especially for a client. I made placebo capsules with starch and sugar; and then he 
asked for more because it had worked. But it’s not easy because they have to look 
like the capsules or pills that the patient normally takes. They have to anyway, for 
the placebo effect to work! (FB, ph) 
Questions about the use of placebos invariably lead pharmacists to bring up 
homeopathy. The extracts of interviews that follow (carried out with ten phar-
macists from different towns in France) show that homeopathy is considered as a 
placebo by some and as a true, but harmless, medicine by others. Qualifying it as a 
placebo is subjective, and pertains to a non-shared cognitive system. Thus, among 
the pharmacists who were asked if any clients ever request placebos, or if they 
ever use or advise placebos, they all ended up mentioning homeopathy, either 
(more often) to associate the two, if they refute any intrinsic efficacy in the product, 
or to the contrary, to disassociate them, if they believe the granules do carry a cer-
tain efficacy6. In all cases, the use is linked to the wish to satisfy clients who want 
to avoid the risks associated with consuming certain medicines.  
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If they ask me, I sometimes give something mild, homeopathy for example, it’s 
not bad, it can’t do any harm. We have no proof that it is effective so it is a bit of a 
placebo. For example, I give homeopathy for a child whose ears hurt when on an 
aeroplane. Anyhow, sucking on granules makes them swallow, so it will unblock 
their ears; this can also be done with a sweet, but these pills make it seem more 
serious. (OD, ph) 
In other cases, a placebo is not asked for explicitly, but the pharmacist perceives 
the request to be implicit. 
When a mother asks me for something to calm her child, she wants something 
mild, with no side effects. So I propose homeopathy. To me, it is a placebo. To the 
patients, it is not an explicit request for a placebo, it is there but hidden. She might 
say to me for example: ‘If he has his three granules, he stops crying! (SE, ph) 
Sometimes the patients ask me for something gentle for a family member; well it’s a 
bit like asking for a placebo, even if they don’t say it openly. For example, a mother 
who asks for something for her child who is stressed about school. The most impor-
tant thing is that it is not harmful, so as to not feel guilty; it takes the blame away 
from her, because if she gives her son something with side-effects, she feels guilty. 
And so we use homeopathy, because there, there is no impact on the physiology of 
the organism. (AL, ph) 
If they ask me for something harmless for a family member to avoid giving him/
her anxiolytics, we can also give them homeopathy. For the patients to trust it and 
for it to work, I tell them: ‘don’t take more than so many per day’; when in fact, they 
can take as many as they like! It’s true that it prevents any side effects for elderly 
people because hypnotics can lead to memory loss! There is a lot of talk about Alz-
heimer’s, and with all these excessive prescriptions of psychoactive drugs, people 
are scared! Personally, I am pretty rational; homeopathy is not proven. Of course, 
we can’t treat everything with homeopathy, because we can’t treat everything with 
placebos! (FB, ph)
This position resonates with the works of authors such as Jonas, Katchup & 
Linde (2003), who stressed that double blind randomised clinical trials against 
placebos showed that for some afflictions there was no difference between the 
results obtained by placebo and by homeopathy, and they conclude that a large 
majority of the therapeutic effects of homeopathy rely on the placebo effect. 
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But not all pharmacists believe homeopathy is a placebo. Mrs B is trained in 
homeopathy and displays her qualification certificate in her pharmacy. She said: 
I have never been asked for a placebo. Sometimes they want something extra, they 
ask for homeopathy for example because they are less afraid of it, because there 
are no adverse side effects. I only give them this if they ask for it as an extra, not 
to replace a prescribed medicine. But I always give them something real; never a 
placebo. Something like homeopathy or herbal medicine. (Mrs B, ph)
They never ask me for placebos and I never give them. I sometimes give something 
with no adverse side effects, for example sea water instead of nose drops, or herbal 
teas rather than antibiotics, for example for cystitis. They are not placebos since 
there is still a mechanical action. Or also homeopathy, but I never give placebos. 
(RM, ph) 
The idea that homeopathic medicine has an active principle or a ‘mechanical 
action’ is based on the underlying belief system according to which the active 
principle of the substance (vegetable, animal or mineral) used still works, even 
though it is highly diluted, since homeopathy is based on the principle of simila-
rity, the theory that a substance with a certain effect would have the inverse effect 
when heavily diluted. 
We can note here that, among the pharmacists who say they suggest their cli-
ents take homeopathy, some do so to illustrate their use of placebos, while other 
to prove that, in response to patient requests for ‘something mild’, they always 
prescribe ‘real medicines’. Consequently, when questioned about their uses of pla-
cebos, some mention homeopathy to answer in the affirmative, while others do so 
to respond in the negative.  
The actors’ ethical positions
As opposed to ‘impure’ placebos that do possess an active principle but are indi-
cated for other pathologies, Lemoine (1996) thinks that ‘the pure placebo is a pure 
lie’ (p.35). The different positions on the ethical dimension of this matter highlight 
attitudes that are subject to moral judgements. Is it ethical to prescribe placebo 
drugs for therapeutic ends? The ethical question is generally raised in reference 
to ‘pure’ placebos. However, it can also be applied to the prescription of impure 
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placebos if the person who prescribes or advises them is convinced they will be 
ineffective in the situation in question.  
The social actors (users and pharmacists) never mention the subject of place-
bos without linking their words and observations concerning their uses to ethical 
considerations. Their arguments to justify their use, or refusal, of placebos mobi-
lise ethical or therapeutic reasons in unequal proportions that vary depending on 
the individuals. And the alchemy between these two types of reasons forms the 
basis for how they choose to act.
Some pharmacists believe using placebos is perfectly ethical in that they judge 
the desired (therapeutic) effect to be beneficial to the patient. Various studies have 
shown that doctors sometimes deem recourse to placebos to be ethical7, and we 
can see that these pharmacists have developed analogous postures. Others, on the 
other hand, condemn this use, also for ethical reasons. Among the stances that 
are ethically against the use of placebos, we find the argument that administering 
a placebo risks damaging the relationship of trust between patient and health 
professional if the patient discovers the truth. For this same reason, Bok (1999) 
condemns the use of placebos as a deceptive practice and underlines the risk of 
eroding patient trust – a trust that is indispensable in all health care relationships. 
Another reason for disagreeing with the practice is that the use of a placebo is 
a way of discrediting the person’s complaint. This position is supported by the 
American Pain Society who oppose the use of placebos to alleviate pain in clinical 
practice partly because, according to the bioethical law, patients should be infor-
med and should give their consent for all medical treatment and partly because 
the analgesic effect of a placebo does not provide useful information on the origin 
and severity of the pain, and that the deceptive use of placebos is a means of dis-
crediting the patients’ perceptions of pain (Sullivan et al., 2005). 
Some pharmacists express rather extreme ethical reservations: 
I have never given a placebo to a patient, I find that shocking! I have never made 
any and would refuse if I was asked. That would be like a mechanic hitting the bon-
net three times with a hammer instead of repairing your car! (SR, ph) 
I have an ethical position on that: no placebos! (LE, ph)
But they can also be more moderate: 
I agree with using placebos if the case is well understood. Sometimes, I sell them 
to clients who ask for a little something for their mother, but only if the patients are 
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being monitored by a doctor. There, we can use a placebo. We have to ensure we are 
not putting the person in danger. If the treatment is being closely checked by the 
children (or someone who is physically and psychologically close to the patient), 
placebos can be given at home, in addition to corticoids for example. When the 
request comes from the family, and the patient is already taking a large amount of 
medicines and they want to ease and reduce this medication load (for example to 
avoid pharmaceutical hepatitis from excessive doses of paracetamol); well, in that 
case, why not use a placebo? (JLF, ph)
The position is more ambiguous when the disassociation between placebos and 
homeopathy is based on a legislative framework and reluctance to give placebos is 
expressed in terms of the legal context: 
I never give placebos. There is a degree of ‘psychological manipulation’ that I don’t 
like. I sometimes give homeopathy; that is acceptable, but not placebos. Anyway, 
the law prohibits it. (RM, ph)
In any case, homeopathy is our only option. We can’t advise a true placebo, because 
if they found out, we would be in trouble! (AL, ph).
To understand the meaning and ramifications of these diverse positions, they 
should be put in perspective with the legal context in which the placebo is con-
ceptualised in France. Yet, as Guimet (2012) notes, no recommendations exist for 
clinical practice on the use of placebos in France, even though the placebo effect 
and placebo medicines in medical practice are explicitly mentioned in the medical 
curriculum (see: Scientific Council of Medicine, Pedagogic objectives of the 2nd cycle 
of medical studies (years 4-6), updated in June 2011). However, the use of placebos 
can only be considered compatible with the French legislation if it is undertaken 
with the patient’s informed consent, as stipulated in the French patient rights law 
of 4th March 2002.  This law stipulates that in the light of information and advice 
supplied by healthcare professionals and in consultation with them, all patients 
are entitled to take decisions regarding their own health, and specifies that the 
information should notably include the treatments proposed and their utility. We 
can see that the way this law is interpreted leads some to believe the deceptive 
use of placebos to be inadmissible (in that it does not respect the principle of pa-
tient autonomy), while it leads others to justify the practice based on the idea that 
placebos can be useful in improving patient health. This ambiguity can be found 
in the definition of a medicine by the Public Health Code (Code de la Santé Pub-
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lique): ‘Any substance or combination of substances presented as [my italics] posses-
sing curative or preventative properties for human beings or animals… in view 
of restoring, correcting or modifying their physiological functions..’, and is also 
present in the writings of the French National Medical Council (Ordre National des 
Médecins) (2012): ‘In medical practice, the placebo effect is a therapeutic means that 
should not be neglected but ethical behaviour is required in using it in order for 
the ritual of the consultation to reach its term. The doctor, in prescribing a placebo, 
wants to please or does so to avoid a useless prescription [my italics]. The doctor-pa-
tient relationship adds value to the prescription of a placebo’ (p. 28). On the other 
hand, because homeopathic medicines have a Marketing Authorisation, they do 
not raise such ethical dilemmas for pharmacists, even when these latter consider 
them to be equivalent to placebos. 
Discussion
As we have seen, the use of placebos for therapeutic reasons (in other words, the 
quest for efficacy with the least iatrogenic risk)8 sometimes comes up against a re-
fusal of placebos for ethical reasons. For some, the ethical position on the subject 
consists of thinking that the only situation in which it is legitimate to prescribe a 
placebo medicine would be when no known active treatment is available, either 
because it allows results to be obtained, or for the psychological wellbeing of the 
patients (to comfort them). This position can also be found amongst users: Mrs S, 
a retired 75-year-old secretary, is in favour of the prescription of placebos. She as-
sumes that her father, who was suffering from cancer and has since died, received 
placebos from his doctor. She is happy about this because she thinks that it com-
forted him and that, ‘in any case, there was nothing that could cure his problem 
at that time’. 
The debate on whether using placebos is ethical or not relates to the question 
of their social acceptability. It is noticeable that the positions are based on diffe-
rent values and stakes, some in line with the principle, others with the result. The 
position based on the principle consists of believing that placebos should never 
be used except in therapeutic trials, out of respect for the patient. Whereas the 
position based on the result says that there is no deception on the product and its 
claimed efficacy if the patient experiences an improvement because he/she be-
lieves he/she will get better, in other words, if there are results. Skrabanek and 
McCormick (1998) go as far as asking: ‘why is it a deception to administer a pla-
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cebo when the large majority of current therapeutics do not give better results?’ 
(p. 14). Here, the judgement is based on the benefits. The ethics is not based on 
principle but on pragmatism, depending on its utility. Thus there exist two main 
attitudes to placebos that emerge from the actors’ perceptions; that of the ‘princi-
plists’ as opposed to the ‘utilitarianists’. In this latter category we find those who, 
like LE (ph), believe: 
We should encourage people not to accustom their children to solving their pro-
blems with medication, and we should propose homeopathy for example. Then, 
even if there is no effect, it is not a placebo (LE, ph).
This position is disputed by those who think using placebos risks, in contrast, 
reinforcing the patient’s belief that recourse to medication is obligatory when in 
fact looking for a  psychotherapeutic treatment or improving one’s lifestyle (sleep-
ing hours, work organisation, nutrition) would be better alternatives.
It is interesting to note that the notion of ethical risk disappears when homeo-
pathy is used, even when the pharmacist is convinced that there is no active prin-
ciple in these substances. This leads us to note that the question cannot be reduced 
to one of being either for or against the use of placebos, and that it must be addres-
sed in a much more complex way to the extent that not only does the evaluation 
of the ethical nature of the use of placebos depend on the context in which it is 
applied, but that the very definition of what a placebo is varies according to the 
individuals’ cognitive system. In a more moderate manner, some professionals 
who support the use of placebos think that such prescriptions are ethical when 
one is aiming to act on the symptoms but not when one is claiming to act on the 
illness itself. 
Diverse attitudes can also be observed among the patients or users. Some would 
like to be able to be fooled with placebos in order to manage their affliction and to 
recover with the least possible physiological costs, that is to say without poisoning 
themselves or without experiencing the negative effects of real medicines, while 
others are very resistant to the idea that they could be deceived, saying they want 
to keep perfect control of their bodies and thus they denounce, on principle, the 
deception they would be subject to. Others again are totally against it for themsel-
ves but not for their relatives. The patients’ attitudes to placebos partly echo the 
pharmacists’ positions on the ethical or non-ethical nature of their use, insofar as 
they give rise to the construction of differing value systems, some in line with the 
principle, others with the result. 
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Conclusion
The material gathered enables me to propose several conclusions:
1) As regards the ‘placebo effect’ with officinal advice, there is, in addition to the 
‘doctor effect’, what can be called the ‘pharmacist effect’ since it is the phar-
macist who dispenses the product, beyond even the medical prescription 
– whether it is a case of advising ‘impure’ placebos, suggesting homeopathic 
granules, or making ‘pure’ placebos. But to these effects we should add a ‘tru-
sted person effect’, since family medication can take place outside the phar-
macist-user relationship and this effect can result from trust put in a family 
member or close friend9, or from the patients’ conviction in the competence of 
the person advising them.   
2) If choosing a placebo is a means of avoiding certain medicines or the risks as-
sociated with them (such as antibiotics, anti-inflammatories and psychoactive 
drugs), it is also a means of medicalizing a problem without pharmaceuticali-
zing it. 
3) Beyond the distinction between ‘pure’ and ‘impure’, there exist situations 
where people use placebos that could be called ‘of the third type’ since their 
status varies depending on the actors. This is the case for homeopathy and 
anti-arthritics for example, as we have seen above.  
4) Although some pharmacists and users qualify homeopathy as a placebo or 
a substance that produces a placebo effect, the ethical question does not ap-
pear to trouble them when using homeopathic medicines, even when the 
pharmacist uses them solely for their virtues as a placebo. The legal status of 
homeopathy as a ‘medicine’ exempts the pharmacist from ethical questioning 
even when he/she believes it to be a placebo, and lets the clients believe that 
it is a medicine endowed with an efficacy equivalent to allopathic medici-
nes, with the only difference being the absence of adverse side-effects. Thus, 
using homeopathy does not pose ethical problems to those very people who 
believe it is totally devoid of efficacy when such questions would be raised 
for any official placebo. The legal recognition of homeopathy in France allows 
pharmacists to exonerate themselves from a professional practice they would 
otherwise judge to be non-ethical. The relationship between therapeutic 
choice and ethical choice is formed around the ambiguous and variable status 
of the concept of placebo. 
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Alongside the strictly technical aspect of the placebo, is the socially constructed 
perception of medicine and efficacy that is contained within the concept of pla-
cebo. This concept is used by the actors to evaluate, measure or signify efficacy; it 
can be applied to a medicine by some to disqualify it and by others to legitimise it. 
As we can see, the starkly contrasting positions which form the basis of the choice 
to use a placebo or not, result from an alchemy of two concerns: the management 
of therapeutic risks and the management of ethical ones.  
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Notes
1: The distinction between the placebo and placebo effect is as follows: the placebo is a sub-
stance with no pharmacological effect, a pharmacologically inert substance given in a 
therapeutic context; the placebo effect however describes the difference between the 
expected therapeutic effect and the observed therapeutic effect. In this regard, the pla-
cebo effect – which Moerman (2000) calls ‘the meaning response’ (p.56) – can describe 
any effect that can be attributed to a medicine, but also to an exploration, act or action 
that is independent from its specific or pharmacological properties (cf. Price, Finiss & 
Benedetti, 2008).   
2: This aspect has been thoroughly investigated in psychology (Zigmond, 1984; Kirsch, 
2011) and in social psychology (Balez, Leroyer & Couturaud, 2014) where the relational 
aspects of medical practice have been underlined. 
3: 12% of respondents used pure placebos while 97% used impure placebos at least once in 
their career. 1% of respondents used pure placebos, and 77% used impure placebos at 
least once per week.
4: It should be noted that the belief that paracetamol is a benign product is common 
amongst French users.
5: The letters, ‘ph’, that appear in parentheses after the fictitious initials of the speakers are 
used to show they are dispensary pharmacists.
6: Evidently, in no way should anthropologists take a personal position on homeopathy, 
nor should we voice any opinions on the validity of its use, but we can examine the uses 
and discourses concerning homeopathy in terms of the link to the issue of placebos.  
7: In the study reported by Howick et al., (2013), most respondents stated placebos (66% 
for pure, 84% for impure) were ethical in some circumstances. Equally, according to 
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Tilburt et al. (2008), most doctors consider the use of placebos to be an ethical practice 
or at least ethically admissible.
8: A lesser but never zero risk since the nocebo effect can sometimes occur.  
9: This relationship of trust is not reduced to intra-family relationships, and can be wid-
ened to the friendship network. 
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